drugset / Trial / NCT00735761

Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis in Immunocompromised Patients

NCT00735761

Phase 3 Completed 201 enrolled Medivir
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the episode duration of a herpes labialis recurrence in immunocompromised patients treated with ME-609 or Acyclovir.

Timeline

Start
2006-12
Primary completion
2007-09
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acyclovir Small molecule 5 % Topical
Subject Hydrocortisone Other / unclassified 1 % Topical

Indications